Your browser doesn't support javascript.
loading
Survival outcomes and treatment experience of 124 patients with primary central nervous system lymphoma.
Tang, Ziqing; Wu, Geting; Tan, Fang; Long, Yang; Hong, Jidong; Lyu, Zhiping; Wei, Rui.
Afiliação
  • Tang Z; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Wu G; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
  • Tan F; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
  • Long Y; Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.
  • Hong J; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Lyu Z; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
  • Wei R; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Strahlenther Onkol ; 200(9): 760-773, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38466403
ABSTRACT

PURPOSE:

Primary central nervous system lymphoma (PCNSL) is a rare malignancy of the central nervous system with high invasiveness. There is little consensus on the treatment of PCNSL. This study retrospectively studied data from PCNSL patients in a single center to summarize treatment experience and explore prognostic factors.

METHODS:

Survival curves were drawn using the Kaplan-Meier method and prognostic factors were analyzed using Cox's hazards model.

RESULTS:

In multivariate analysis, cerebrospinal fluid lactic acid dehydrogenase (CSF LDH; p = 0.005 and p = 0.002), neutrophil to lymphocyte ratio (NLR; p = 0.014 and p = 0.038), and completion of four cycles of induction therapy (p < 0.001and p < 0.001) were significant and independent predictors of overall survival (OS) and progression-free survival (PFS), respectively.

CONCLUSION:

On the basis of this study, we propose that PCNSL patients should receive early induction therapy with sufficient cycles. Subsequent consolidation therapy can prevent relapses and improve survival. In patients with PCNSL, the independent prognostic factors for OS and PFS were CSF LDH level, NLR, and full cycles of induction therapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Sistema Nervoso Central Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Strahlenther Onkol Assunto da revista: NEOPLASIAS / RADIOTERAPIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Sistema Nervoso Central Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Strahlenther Onkol Assunto da revista: NEOPLASIAS / RADIOTERAPIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China